AGD-10666-07240
3 vaccinations
3 coded responses
16 check-ins
3 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 56-60
- ZIP prefix
- 981 / WA
- Registered
- 2021-12-01
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-27
Dose 1 — Pfizer-BioNTech
-
2021-04-17
Dose 2 — Pfizer-BioNTech
-
2021-12-01
Registered in v-safe
-
2021-12-01
Dose 3 — Pfizer-BioNTech
- 2021-12-01
-
2021-12-02
Health check-in — days 1–6 daily, dose 3Feeling: Good · Site: Pain, Redness · Fatigue or tirednessAdult check-in
-
2021-12-03
Survey response — days 1–6 daily, dose 3MedDRA: Dizziness — Feeling: Good · Site: Pain, Redness · Fatigue or tirednessFree text: Some lightheaded mess--don't know if relatedMedDRA releases: 2024-11 · check-in free text available
- 2021-12-04
- 2021-12-05
- 2021-12-06
- 2021-12-07
- 2021-12-08
- 2021-12-15
- 2021-12-22
- 2021-12-29
- 2022-01-05
- 2022-01-12
- 2022-03-03
-
2022-06-01
Survey response — 6 months, dose 3MedDRA: Balance disorder, Dizziness, Inflammation, Labyrinthitis, Physiotherapy, Pre-existing disease, Tinnitus, Vertigo, Vestibular migraine — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visit, Emergency room or emergency department visitFree text: Symptoms: Labyrinthitis; potentially Ménière's disease. Chronic auditory nerve inflammation and tinnitus. Balance and dizziness (vertigo) at onset in March have improved but inflammation/tinnitus/vestibular migraines persist. · Healthcare visit (other): Vestibular therapistMedDRA releases: 2024-11 · check-in free text available
-
2022-06-01
Report sent to call center — 6 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · Outpatient clinic or urgent care clinic visit · Emergency room or emergency department visit · 1 call case(s)
- 2022-06-02
-
2022-06-03
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
-
2022-12-01
Survey response — 12 months, dose 3MedDRA: Postmenopausal haemorrhage, Vestibular neuronitis — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visit, Emergency room or emergency department visitFree text: Last time reported acute left ear neuritis, continuing since March 2022. In July and October 2022 had post menopausal bleeding (15 years after menopause). Endometrial biopsy negative.MedDRA releases: 2024-11 · check-in free text available
-
2022-12-01
Report sent to call center — 12 months, dose 3Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · Outpatient clinic or urgent care clinic visit · Emergency room or emergency department visit · 1 call case(s)
- 2022-12-02
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-27 | Pfizer-BioNTech | No |
| 2 | 2021-04-17 | Pfizer-BioNTech | No |
| 3 | 2021-12-01 | Pfizer-BioNTech | No |
Call center
2 call center cases
1 successful · 1 unsuccessful
Free text
Release 10 — days 1–6 daily, dose 3
Systemic reaction (other): Some lightheaded mess--don't know if related
Release 11 — 6 months, dose 3
Symptoms: Labyrinthitis; potentially Ménière's disease. Chronic auditory nerve inflammation and tinnitus. Balance and dizziness (vertigo) at onset in March have improved but inflammation/tinnitus/vestibular migraines persist.
Healthcare visit (other): Vestibular therapist
Release 12 — 12 months, dose 3
Symptoms: Last time reported acute left ear neuritis, continuing since March 2022. In July and October 2022 had post menopausal bleeding (15 years after menopause). Endometrial biopsy negative.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Physiotherapy | · | · | ✓ |
| SD | Balance disorder | · | · | ✓ |
| SD | Dizziness | · | · | ✓ |
| SD | Inflammation | · | · | ✓ |
| SD | Labyrinthitis | · | · | ✓ |
| SD | Postmenopausal haemorrhage | · | · | ✓ |
| SD | Pre-existing disease | · | · | ✓ |
| SD | Tinnitus | · | · | ✓ |
| SD | Vertigo | · | · | ✓ |
| SD | Vestibular migraine | · | · | ✓ |
| SD | Vestibular neuronitis | · | · | ✓ |
| SRO | Dizziness | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release